Komori
OncoTherapy Science (4564) · InitiativeReframed

Agreement with Advanced Genomics APAC for domestic cancer genetic testing services in Japan

First written in FY2025. 1 of 2 entries say "Reframed", first in FY2026-H1. Latest entry: FY2026-H1.

2entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20252025: 22025
Same theme, other companies
Expanding Sales of Clinical Genetic Testing Services and Test KitsA theme 4 companies write about · 0 as a headwind · 4 as a tailwind

0 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1ReframedAnnual report

    「CPM has entered into an exclusive service-provider agreement in Japan with Nonacus Limited. (operations changed from Advanced Genomics APAC Co., Ltd. to Nonacus; hereinafter, “Nonacus”) for the GALEAS Bladder bladder cancer screening test marketed by Nonacus, as well as a service-provider agreement in Japan covering Nonacus's other cancer genetic tests and related services.」

    The agreement to provide bladder cancer screening tests and other services in Japan has been updated and is now positioned as an agreement with Nonacus, following the transfer of operations changed from Advanced Genomics APAC to Nonacus.
  2. FY2025First statedAnnual report

    「CPM has entered into an exclusive service-provider agreement in Japan with Advanced Genomics APAC Co., Ltd. for the GALEAS Bladder bladder cancer screening test marketed by Advanced Genomics APAC, as well as a service-provider agreement in Japan covering Advanced Genomics APAC's other cancer genetic tests and related services.」

    CPM has for the first time disclosed that it entered into agreements with Advanced Genomics APAC to provide services in Japan for bladder cancer screening tests and other products.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Agreement with Advanced Genomics APAC for domestic cancer genetic testing services in Japan | OncoTherapy Science,Inc. (4564) | Komori